Janknegt RA - Search Results

1

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.

Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Dijkman GA, et al. Among authors: janknegt ra. J Urol. 1997 Jul;158(1):160-3. doi: 10.1097/00005392-199707000-00051. J Urol. 1997. PMID: 9186345 Clinical Trial.

2

Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.

Dijkman GA, Fernandez del Moral P, Debruyne FM, Janknegt RA. Dijkman GA, et al. Among authors: janknegt ra. Eur Urol. 1995;27(3):196-201. doi: 10.1159/000475160. Eur Urol. 1995. PMID: 7601182 Clinical Trial.

3

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.

Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al. Janknegt RA, et al. J Urol. 1993 Jan;149(1):77-82; discussion 83. doi: 10.1016/s0022-5347(17)36003-2. J Urol. 1993. PMID: 7678043 Clinical Trial.

4

Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.

Janknegt RA, Boon TA, van de Beek C, Grob P. Janknegt RA, et al. Urology. 1997 Mar;49(3):411-20. doi: 10.1016/s0090-4295(96)00496-7. Urology. 1997. PMID: 9123707 Clinical Trial.

5

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.

Janknegt RA, Chapple CR. Janknegt RA, et al. Eur Urol. 1993;24(3):319-26. doi: 10.1159/000474321. Eur Urol. 1993. PMID: 7505224

6

Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.

Janknegt RA. Janknegt RA. Cancer. 1993 Dec 15;72(12 Suppl):3874-7. doi: 10.1002/1097-0142(19931215)72:12+<3874::aid-cncr2820721722>3.0.co;2-#. Cancer. 1993. PMID: 8252507 Clinical Trial.

7

Oral desmopressin as a new treatment modality for primary nocturnal enuresis in adolescents and adults: a double-blind, randomized, multicenter study. Dutch Enuresis Study Group.

Janknegt RA, Zweers HM, Delaere KP, Kloet AG, Khoe SG, Arendsen HJ. Janknegt RA, et al. J Urol. 1997 Feb;157(2):513-7. J Urol. 1997. PMID: 8996345 Clinical Trial.

8

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.

Smith JA Jr, Lange PH, Janknegt RA, Abbou CC, deGery A. Smith JA Jr, et al. Among authors: janknegt ra. J Urol. 1997 Apr;157(4):1329-34. J Urol. 1997. PMID: 9120932 Clinical Trial.

9

Treatment with desmopressin in severe nocturnal enuresis in childhood.

Janknegt RA, Smans AJ. Janknegt RA, et al. Br J Urol. 1990 Nov;66(5):535-7. doi: 10.1111/j.1464-410x.1990.tb15005.x. Br J Urol. 1990. PMID: 2249126 Clinical Trial.

10

Electrically stimulated gracilis sphincter (dynamic graciloplasty) for treatment of intrinsic sphincter deficiency: a pilot study on feasibility and side effects.

Janknegt RA, Heesakkers JP, Weil EH, Baeten CG. Janknegt RA, et al. J Urol. 1995 Nov;154(5):1830-3. J Urol. 1995. PMID: 7563357 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters